Zymeworks and Kairos Therapeutics Enter into Strategic Partnership

VANCOUVER, British Columbia–Zymeworks Inc. and Kairos Therapeutics Inc., both privately-held biotech companies headquartered in Vancouver, today announced they have entered into a strategic partnership whereby Zymeworks, a leader in the development of bi-specific and multi-specific antibodies, has made an undisclosed equity investment in Kairos which specializes in the discovery and development of antibody drug conjugates (ADCs) and is a spin-out of The Centre for Drug Research and Development (CDRD). Under the terms of this agreement, Zymeworks and Kairos also have the option to merge to further integrate their respective platforms, resources and pipelines to accelerate the development of novel anti-cancer biotherapeutics.

Subscribe to get the latest news